Clene Inc. will join a panel on neurodegenerative diseases at the Maxim Growth Summit on October 22, 2025.
Quiver AI Summary
Clene Inc., a clinical-stage biopharmaceutical company focused on improving mitochondrial health to treat neurodegenerative diseases like ALS and MS, announced that its management will participate in a panel discussion at the Maxim Growth Summit on October 22, 2025, in New York City. The panel will focus on innovative approaches to neurodegenerative diseases, and Clene will also host one-on-one investor meetings. Clene's investigational therapy, CNM-Au8®, targets mitochondrial function and reduces oxidative stress to enhance neuronal survival and function. The company operates from Salt Lake City, Utah, with additional R&D and manufacturing in Maryland.
Potential Positives
- Clene Inc. is actively engaging with investors by participating in a panel discussion at the Maxim Growth Summit, showcasing its commitment to transparency and communication.
- The focus of the panel on "Under the Radar Innovators" highlights Clene's innovative approach to neurodegenerative diseases, potentially attracting attention and interest from investors and industry peers.
- Clene's investigational therapy, CNM-Au8®, is positioned as a first-in-class treatment, which may strengthen the company's competitive edge in the biopharmaceutical market.
Potential Negatives
- The press release does not provide any specific updates on the company's clinical trials or product development milestones, which could raise concerns about the progress and efficacy of their investigational therapies.
- Participation in a panel discussion may imply the company is focusing on visibility rather than delivering tangible advancements in research or product development, potentially indicating a lack of substantial news.
- As a late clinical-stage biopharmaceutical company, any delay or lack of progress in bringing products to market could signify deeper issues within the company's pipeline or operational strategy.
FAQ
What is Clene Inc. known for?
Clene Inc. focuses on improving mitochondrial health and neuronal function to treat neurodegenerative diseases.
When will Clene participate in the Maxim Growth Summit?
Clene will participate in the Maxim Growth Summit on October 22, 2025.
Where will the Maxim Growth Summit be held?
The Maxim Growth Summit will take place in New York City, NY.
What is CNM-Au8®?
CNM-Au8® is an investigational therapy that targets mitochondrial function to improve central nervous system cell survival.
How can investors schedule meetings with Clene's management?
Investors can contact their Maxim representative to schedule 1x1 meetings with Clene's management.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$CLNN Insider Trading Activity
$CLNN insiders have traded $CLNN stock on the open market 7 times in the past 6 months. Of those trades, 0 have been purchases and 7 have been sales.
Here’s a breakdown of recent trading of $CLNN stock by insiders over the last 6 months:
- RESONANCE LLC GENERAL has made 0 purchases and 7 sales selling 6,261 shares for an estimated $27,444.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$CLNN Analyst Ratings
Wall Street analysts have issued reports on $CLNN in the last several months. We have seen 3 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- D. Boral Capital issued a "Buy" rating on 09/25/2025
- Benchmark issued a "Buy" rating on 09/10/2025
- Jones Trading issued a "Buy" rating on 04/23/2025
To track analyst ratings and price targets for $CLNN, check out Quiver Quantitative's $CLNN forecast page.
$CLNN Price Targets
Multiple analysts have issued price targets for $CLNN recently. We have seen 5 analysts offer price targets for $CLNN in the last 6 months, with a median target of $31.0.
Here are some recent targets:
- Jason Kolbert from D. Boral Capital set a target price of $23.0 on 09/25/2025
- Bruce D. Jackson from Benchmark set a target price of $31.0 on 09/10/2025
- Sumant Kulkarni from Canaccord Genuity set a target price of $48.0 on 08/18/2025
- Justin Walsh from Jones Trading set a target price of $30.0 on 04/23/2025
Full Release
SALT LAKE CITY, Oct. 15, 2025 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS), today announced that management will participate in a panel discussion at the Maxim Growth Summit and host 1x1 investor meetings.
Date:
October 22, 2025
Location:
New York City, NY
Panel Discussion:
Neurodegenerative Diseases Panel – Under the Radar Innovators in One of the Most Challenging Therapeutic Categories
1x1 Meetings:
Please contact your Maxim representative
About Clene
Clene Inc., (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., is a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis, Parkinson’s disease, and multiple sclerosis. CNM-Au8
®
is an investigational first-in-class therapy that improves central nervous system cells’ survival and function via a mechanism that targets mitochondrial function and the NAD pathway while reducing oxidative stress. CNM-Au8
®
is a federally registered trademark of Clene Nanomedicine, Inc. The company is based in Salt Lake City, Utah, with R&D and manufacturing operations in Maryland. For more information, please visit
www.clene.com
or follow us on
X (formerly Twitter)
and
LinkedIn
.
Investor Contact
Kevin Gardner
LifeSci Advisors
[email protected]
617-283-2856
